GPC/ Altana: A New Middle Market for Big Genomics Deals? Probably Not

Even as Big Pharma deals for big genomics technology tapers off, GPC Biotech and mid-sized Altana are forging ahead with their own program: a $100 million alliance to set up a genomics center for Altana. Separately, Altana could pay GPC milestones on scientific and clinical success. But this deal doesn't signal a trend towards mid-sized company dealmaking. First, both companies have collaborated before and second, they aren't interested in technology transfer.

Among Big Pharma, the market for big genomics technology deals is well nigh saturated, or so one would be led to believe by the stunning drop-off in research-stage deals of any significant size. The name of the game today is products—which is why the last two major deals out of Millennium Pharmaceuticals Inc. both hinge, for their success, on delivery of compounds into the clinic, not simply targets or technology (though access to Millennium's discovery platform was clearly a motivating factor for both Aventis SA [See Deal] and Abbott Laboratories Inc. [See Deal] (See "Dealmaking for the Revolution," IN VIVO, March 2001 [A#2001800063.)

Which isn't to say there's no market for big technology deals—as the recent arrangement between GPC Biotech AG and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business Strategy

More from In Vivo

Deals In Depth: June 2025

 
• By 

Five $1bn+ alliances were penned in June, and four exceeded $2bn.

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By 

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

Podcast: Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

 
• By 

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.